CADL News and Press, Candel Therapeutics Inc.

NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on July 6, 202...

2026-07-04 02:06:05 ET Editor's note: Seeking Alpha is proud to welcome Max Arnoldi as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium a...

Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) with progressive disease despite prior pembroliz...

Appointment supports planned Biologics License Application (BLA) submission in the fourth quarter of 2026 and potential 2027 launch of aglatimagene besadenovec in localized prostate cancer NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Na...

Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with curative intent combined with aglatimagene besadenovec (aglatimagene) plus valacyclovir compared to...

2026-05-15 22:20:42 ET Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, 2026 1:00 PM EDT... Read the full article on Seeking Alpha For further details see: Candel Therapeuti...

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prostate cancer–specific disease-free survival (DFS) of 39% after aglatimagene administration co...

2026-05-14 08:07:57 ET More on Candel Therapeutics Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling Candel gains on additional mid-stage trial data for lead asset Candel Therapeutics launches $100M public stock offering; shares down Seeking...

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026 Announced purpose-built commercial partnership with EVERSANA ® to support potential U.S. launch of agl...

2026-05-11 18:50:04 ET Candel Therapeutics, Inc. (CADL) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 4.19%. The average open to low on the day of earnings was -4.61%. The average open...